SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Attovia Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

Jennifer Martin
1700 Seventh Ave, Suite 1120,
Seattle, WA, 98101
(206) 451-8040

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/06/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences Public Fund, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only

4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 760,327.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 760,327.00

11	Aggregate amount beneficially owned by each reporting person 760,327.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 1.7 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLSP, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 760,327.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 760,327.00

11	Aggregate amount beneficially owned by each reporting person 760,327.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 1.7 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLSP, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 760,327.00
	9	Sole Dispositive Power 0.00

	10	Shared Dispositive Power 760,327.00
11	Aggregate amount beneficially owned by each reporting person 760,327.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 1.7 %	
14	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences XI, L.P.	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)	
3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 6,154,213.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 6,154,213.00
11	Aggregate amount beneficially owned by each reporting person 6,154,213.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	

13	Percent of class represented by amount in Row (11) 13.5 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XI, L.P.		
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)		
3	SEC use only		
4	Source of funds (See Instructions) AF		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐		
6	Citizenship or place of organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00	
	8	Shared Voting Power 6,154,213.00	
	9	Sole Dispositive Power 0.00	
	10	Shared Dispositive Power 6,154,213.00	
11	Aggregate amount beneficially owned by each reporting person 6,154,213.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐		
13	Percent of class represented by amount in Row (11) 13.5 %		
14	Type of Reporting Person (See Instructions) PN		

Comment for Type of The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

Reporting Person:

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XI, L.L.C.	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)	
3	SEC use only	
4	Source of funds (See Instructions) AF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 6,154,213.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 6,154,213.00
11	Aggregate amount beneficially owned by each reporting person 6,154,213.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 13.5 %	
14	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences XII, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 54,163.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 54,163.00

11	Aggregate amount beneficially owned by each reporting person 54,163.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 0.1 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XII, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)

3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 54,163.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 54,163.00

11	Aggregate amount beneficially owned by each reporting person 54,163.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 0.1 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XII, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization

		DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00	
	8	Shared Voting Power 54,163.00	
	9	Sole Dispositive Power 0.00	
	10	Shared Dispositive Power 54,163.00	
11		Aggregate amount beneficially owned by each reporting person 54,163.00	
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13		Percent of class represented by amount in Row (11) 0.1 %	
14		Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 45,579,017 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, $0.0001 par value per share

(b) Name of Issuer:

Attovia Therapeutics, Inc.

(c) Address of Issuer's Principal Executive Offices:

1091 Industrial Road, Suite 310, San Carlos, CALIFORNIA , 94070.

Item 2. Identity and Background

(a) The entities filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C.

(b) The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304

(c) FLSPF is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. FLS XI is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. FLS XII is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner of FHMLS XII, L.P.

(d) During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C.- Delaware, U.S.A.

Item 3. Source and Amount of Funds or Other Consideration

Prior to the Issuer's initial public offering (the "IPO"), FLS XI purchased from the Issuer in a series of private transactions, (i) 75,350 shares of Common Stock (after accounting for the 9.29-1 reverse stock split effected on July 29, 2026), (ii) 16,250,000 shares of Series A-1 Preferred Stock, (iii) 14,772,727 shares of Series A-2 Preferred Stock, (iv) 11,054,544 shares of Series B Preferred Stock and (v) 8,930,685 shares of Series C Preferred Stock, for an aggregate total purchase price of approximately $59,979,760. In connection with the closing of the IPO, the shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock held by FLS XI automatically converted into shares Common Stock of the Issuer on a 9.29-to-1 basis, respectively, which resulted in FLS XI directly holding 5,565,980 shares of Common Stock of the Issuer. FLSPF, FLS XI and FLS XII also purchased 617,758, 588,235 and 44,007 shares of Common Stock, respectively, from the underwriters of the IPO at the IPO price of $17.00 per share, for an aggregate purchase price of $21,250,000. On August 5, 2026, FLSPF and FLS XII purchased, in multiple transactions at prices ranging from $21.77 to $22.00, inclusive, 93,350 and 6,650 shares of Common Stock, respectively, for an aggregate purchase price of $2,190,790. Both FLSPF and FLS XII undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price. On August 6, 2026, FLSPF and FLS XII purchased, in multiple transactions at prices ranging from $20.36 to $21.88, inclusive, 46,675 and 3,325 shares of Common Stock, respectively, for an aggregate purchase price of $1,061,850. Both FLSPF and FLS XII undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price. On August 7, 2026, FLSPF and FLS XII purchased, in multiple transactions at prices ranging from $19.37 to $20.00, inclusive, 2,544 and 181 shares of Common Stock, respectively, for an aggregate purchase price of $53,728.83. Both FLSPF and FLS XII undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price. All purchases of the securities described herein were for cash and were funded by working capital of FLSPF, FLS XI and FLS XII, as applicable.

Item 4. Purpose of Transaction

The Reporting Persons acquired the Common Stock reported herein for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) Any action similar to any of those enumerated above.

Item 5. Interest in Securities of the Issuer

(a) The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 760,327 shares of Common Stock of the Issuer (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS XI directly holds 6,154,213 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 54,163 shares of Common Stock of the Issuer (the "FLS XII Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.

(b) The information contained in rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5.

(c) Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the FLSPF Shares, the FLS XI Shares or the FLS XII Shares beneficially owned by any of the Reporting Persons, other than the respective limited partners, general partners, members and/or beneficiaries of such Reporting Persons.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Lock-up Agreements The holders of substantially all of the Issuer's pre-IPO capital stock, including the FLS XI, and each of the Issuer's directors and officers, entered into lock-up agreements (the "Lock-Up Agreements") with the representatives of the underwriters of the Issuer's IPO. Pursuant to the Lock-Up Agreements, FLS XI is not permitted, with limited exceptions, for a period of 180 days after the date of the final prospectus related to the IPO, to dispose of or hedge any of the Issuer's securities, except with the prior written consent of Morgan Stanley & Co. LLC, Leerink Partners LLC, Citigroup Global Markets Inc. and RBC Capital Markets, LLC. The description of the Lock-Up Agreements contained in this Item 6 is qualified in its entirety by reference to the full text of the form of Lock-up Agreement filed as Exhibit 99.2 to this Schedule 13D and incorporated by reference herein. Amended and Restated Investors' Rights Agreement On March 31, 2025, certain investors of the Issuer, including FLS XI, entered into the Amended and Restated Investors' Rights Agreement (the "Investors' Rights Agreement") with the Issuer. Under the Investors' Rights Agreement, holders of registrable securities, including certain of the Reporting Persons, can demand that the Issuer file a registration statement or request that their registrable shares be included on a registration statement that the Issuer is otherwise filing, in either case, registering the resale of their shares of Common Stock. These registration rights are subject to conditions and limitations, including the right, in certain circumstances, of the underwriters of an offering to limit the number of shares included in such registration. The description of the Investors' Rights Agreement contained in this Item 6 is qualified in its entirety by reference to the full text of the Investors' Rights Agreement filed as Exhibit 99.3 to this Schedule 13D and incorporated by reference herein.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Joint Filing Agreement Exhibit 99.2 Form of Lock-up Agreement (incorporated by reference to Exhibit A to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A, filed with the SEC on July 29, 2026). Exhibit 99.3 Amended and Restated Investors' Rights Agreement (incorporated by reference to Exhibit 3.1 to the Issuer's Registration Statement on Form S-1, filed with the SEC on July 14, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	08/11/2026

FHMLSP, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	08/11/2026

FHMLSP, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:	08/11/2026

Frazier Life Sciences XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	08/11/2026

FHMLS XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.

Date: 08/11/2026

FHMLS XI, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date: 08/11/2026

Frazier Life Sciences XII, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date: 08/11/2026

FHMLS XII, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date: 08/11/2026

FHMLS XII, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date: 08/11/2026

EXHIBIT 99.1

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Shares of Common Stock of Attovia Therapeutics, Inc.

Date: August 11, 2026

FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
By: FHMLSP, L.P., its General Partner
By: FHMLSP, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FHMLSP, L.P.
By: FHMLSP, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FHMLSP, L.L.C.

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FRAZIER LIFE SCIENCES XI, L.P.
By: FHMLS XI, L.P., its General Partner
By: FHMLS XI, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FHMLS XI, L.P.
By: FHMLS XI, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FHMLS XI, L.L.C.

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FRAZIER LIFE SCIENCES XII, L.P.
By: FHMLS XII, L.P., its General Partner
By: FHMLS XII, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FHMLS XII, L.P.
By: FHMLS XII, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: August 11, 2026

FHMLS XII, L.L.C.

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer